Raymond James analyst Elliot Wilbur maintained a Buy rating on Teva Pharmaceutical Industries (TEVA) on October 23. The company’s shares closed last Thursday at $9.44.
According to TipRanks.com, Wilbur is ranked 0 out of 5 stars with an average return of -3.4% and a 41.4% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Flexion Therapeutics, and Sol-Gel Technologies.
Teva Pharmaceutical Industries has an analyst consensus of Hold, with a price target consensus of $12.45, representing a 32.2% upside. In a report issued on October 16, Gabelli also upgraded the stock to Buy.
See today’s analyst top recommended stocks >>
Teva Pharmaceutical Industries’ market cap is currently $10.31B and has a P/E ratio of 929.00. The company has a Price to Book ratio of -0.49.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Read More on TEVA:
